GLPwatch

A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese

NCT04016974 · Completed

Last updated 2026-05-28

This study is testing how oral semaglutide tablets are absorbed and processed in the bodies of healthy Chinese adults.

Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 32 people
Who can join Ages 18–55 · all sexes Healthy volunteers accepted.
Timeline Started 2019-10 · est. completion 2021-02
Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04016974 ↗

Description as written by the study sponsor.

This study looks at the way a new medicine tablet called semaglutide moves in and throughout the body over time. It will also look at if the medicine is safe and the body can accept it. The new medicine is planned to treat diabetes. The aim of the study is to see how semaglutide tablets work in healthy people who are Chinese. Participants will either get oral semaglutide tablets or placebo (dummy) tablets - which treatment is decided by chance. The tablet form of semaglutide is a new medicine that cannot be prescribed. Doctors can prescribe semaglutide as an injection only. It is for the treatment of diabetes in some countries. Participants will get 1 tablet per day for 12 weeks (84 days). Participants will get 1 tablet a day to take with up to half a glass of water (maximum 120 mL). Participants must take the tablet first thing in the morning on an empty stomach (water is allowed until 2 hours before taking the tablet). After taking the tablet, participants must not eat or drink anything for at least 30 minutes. After 30 minutes, they can have their first meal of the day and take any other medicines they may need, such as birth control tablets, routine vitamins and use of paracetamol at times.

Treatments tested

Main thing measuredAUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady state
SponsorNovo Nordisk A/S
Conditions studiedHealthy Volunteers, Diabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04016974 ↗